| Bioactivity | Fluasterone is a potent G6PD inhibitor with a Ki of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active[1][2][3]. |
| Target | Ki: 0.51 μM (G6PD) |
| In Vivo | Fluasterone (0.2% and 0.3%; in diet for 39 days) 对糖尿病小鼠有抗高血糖作用[2]。Fluasterone (200 μg/mouse; intradermal injection; once) 抑制 TPA 诱导的急性炎症和表皮增生作用[3]。 Animal Model: |
| Name | Fluasterone |
| CAS | 112859-71-9 |
| Formula | C19H27FO |
| Molar Mass | 290.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schwartz AG, et al. Potential therapeutic use of dehydroepiandrosterone and structural analogs. Diabetes Technol Ther. 2001 Summer;3(2):221-4. [2]. Pashko LL, et al. Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice. Diabetes. 1993 Aug;42(8):1105-8. [3]. Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett. 2001 Jul 10;168(1):7-14. |